Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

58 results about "Totipotent" patented technology

Having to do with cells that are able to develop into any type of cell found in the body.

Use method for de-host extraction test kit of a metagenome sample

PendingCN111088249AImprove effective sequencing dataImprove bindingDNA preparationMicroorganismNuclease
The invention provides a use method for a de-host extraction test kit of a metagenome sample, and relates to the field of biological detection. The method comprises the following steps: pathogen enrichment: a step of adding a sample into a first centrifuge tube with a volume of 1.5 mL, carrying out centrifuging for 5-10 min at a room temperature, and removing a supernatant; host cell lysis: a stepof adding 200-1000 [mu]L of a lysis buffer solution, namely Buffer G1 into the first centrifuge tube, and carrying out incubating at 20-40 DEG C for 10-30 min; host DNA removal: a step of centrifuging the first centrifuge tube at a room temperature for 2-5 min so as to remove a supernatant, adding 200-500 [mu]L of the lysis buffer solution, namely the Buffer G1 and 1-3 [mu]L of totipotent nuclease into the first centrifuge tube again, carrying out incubating at 30-40 DEG C for 10-30 min, carrying out centrifuging so as to remove the supernatant, adding 500-1000 [mu]L of the Buffer G1, and washing a precipitate twice; wall breaking of microbial thalli: a step of adding 100-300 [mu]L of lysozyme to resuspend the precipitate, transferring a resuspension to a lysis tube filled with glass beads, placing the lysis tube at 30-40 DEG C, carrying out incubating for 10-30 min, and carrying out vortex uniform mixing treatment for 5-10 min; and microbial lysis and nucleic acid extraction. The usemethod provided by the invention is wide in application range, good in compatibility, good in extraction effect, high in efficiency and low in cost.
Owner:康为医学检验实验室(泰州)有限公司

Method for extracting sub-totipotent stem cell from chorion of fetal surface of placenta

The invention relates to a method for extracting sub-totipotent stem cells from a chorion of a fetal surface of a placenta. The method comprises the steps of removing an amnion and stagnated blood from the placenta, and then repetitively washing the surface of the placenta to perform sterilization; shearing the chorion of the fetal surface in a glass utensil, removing placenta lobule tissues remained on the surface as much as possible, and shearing the chorion into small blocks; washing small tissue blocks by using a screen and a great amount of normal saline, and removing residual blood cells; performing tissue digestion: performing oscillatory digestion in a constant temperature shaker by using mixed enzymes; adding a proper amount of FBS for termination after digestion, performing filtration through a filter screen, and adding a great amount of normal saline to wash filter residues to obtain cells as many as possible; performing centrifugation, abandoning supernatant, adding saline water for washing and performing centrifugation to obtain mononuclear cells; performing magnetic bead sorting (OCT-4 positive, Nanog positive and STRO-1 negative) to obtain target cells. The invention further relates to the sub-totipotent stem cells obtained by adopting the method and pharmaceutical use thereof. The sub-totipotent stem cells have excellent characteristics.
Owner:BOYALIFE

Chlorophyllous totipotent cell cultures

The subject invention provides totipotent, chlorophyllous, cell cultures of maize. In addition, the methods of producing such cultures are applicable to other related species, including cereals such as rice, oats, barley, and heat. The subject cultures are valuable for herbicide studies, studies for enhancing photosynthesis, and genetic manipulation, such as plastid transformation. The methods of the subject invention are capable of providing high percentages of totipotent cells. These cells are capable of sustained cell division and are competent for regeneration over long periods; they provide high-quality target tissue for nuclear and organelle transformation. The invention also describes methods for the introduction of heterologous DNA into the chloroplast genome. The present invention also provides methods, vectors, and gene constructs for enhancing expression of a recombinant nucleic acid sequence in transgenic plants and plant tissues.
Owner:DOW AGROSCIENCES LLC

Method for production of mesenchymal cell, method for production of tooth, and mesenchymal cell for formation of tooth

The present invention provides a method for producing mesenchymal cells for production of mesenchymal cells for formation of a tooth, the method comprising: culturing totipotent stem cells in the presence of a differentiation inducer to produce a cell population after differentiation induction treatment, the cell population containing CD44-positive and CD29-positive cells or CD44-positive and CD 106-positive cells; and selecting, from the cell population after the differentiation induction treatment, the CD44-positive and CD29-positive cells or CD44-positive and CD 106-positive cells as the mesenchymal cells for the formation of the tooth. The present invention also provides a method for producing a tooth comprising: positioning, in a support carrier capable of retaining cells in a state of contacting therewith, a first cell mass substantially consisting of only either one of mesenchymal cells and epithelial cells and a second cell mass substantially consisting of only the other one of the mesenchymal cells and epithelial cells, the first and second cell masses being not mixed with each other but made to closely contact with each other; and culturing the first and second cell masses; wherein the mesenchymal cells comprise the mesenchymal cells for the formation of the tooth.
Owner:ORGAN TECH

Human adipose sub-totipotent stem cell isolated-culture method and stem cell bank establishing method

The invention discloses a human adipose sub-totipotent stem cell isolated-culture method and a stem cell bank establishing method. The human adipose sub-totipotent stem cell isolated-culture method includes the following steps of human adipose tissue collection, sub-totipotent stem cell separation and obtaining, sub-totipotent stem cell culture and proliferation, sub-totipotent stem cell cryopreservation, product quality control, stem cell bank establishing and stem cell revivifying and annual inspection. Mixed collagenase used by the method can effectively separate sub-totipotent stem cells from adipose tissues, is homogenous in tissue digestion, no obvious tissue residual is produced, the cell activity is good, wall adherence is quick, and the homogeneity is good. Cryopreservation liquid adopted by the method can effectively maintain the cell activity, a gradient cooling box is adopted to cryopreserve cells, the cell activity is not affected, and the human adipose sub-totipotent stem cell isolated-culture method is simple in operation, convenient and high in efficiency.
Owner:GENESIS STEMCELL REGENERATIVE MEDICINE ENG CO LTD

Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells

Activated human embryos produced by therapeutic cloning can give rise to human totipotent and pluripotent stem cells from which autologous cells for transplantation therapy are derived. The present invention provides methods for producing activated human embryos that can be used to generate totipotent and pluripotent stem cells from which autologous cells and tissues suitable for transplantation can be derived. In one embodiment, the invention provides methods for producing activated human embryos by parthenogenesis; in another embodiment, the invention provides methods for producing activated human embryos by somatic cell nuclear transfer whereby the genetic material of a differentiated human donor cell is reprogrammed to form a diploid human pronucleus capable of directing a cell to generate the stem cells from which autologous, isogenic cells for transplantation therapy are derived. The ability to create autologous human embryos represents a critical step towards generating immune-compatible stem cells that can be used to overcome the problem of immune rejection in regenerative medicine. The activated human embryos produced by the present invention also provide model systems for identifying and analyzing the molecular mechanisms of epigenetic imprinting and the genetic regulation of embryogenesis and development.
Owner:ADVANCED CELL TECH INC

Method for induced differentiation of human placenta sub-totipotent stem cells to obtain cardiac muscle cells and application thereof

The invention discloses a method for induced differentiation of human placenta sub-totipotent stem cells to obtain cardiac muscle cells. The method comprises the following steps: inoculating human placenta sub-totipotent stem cells into a 24-pore plate containing a stem cell culture medium; after cell attachment, removing the stem cell culture medium; and adding a cardiac muscle cell culture medium for culture for 28 days, and changing the culture medium every 3 days. The stem cell culture medium comprises a DMEM culture medium, hydroxyethyl starch, human serum albumin, potassium bicarbonate, ethylenediamine tetraacetic acid sodium salt, sodium selenite, transferrin, hyaluronic acid, taurine, placental growth factors, fibroblast growth factors, glutathione, lipoic acid, astragalus polysaccharide, codonopsis pilosula polysaccharide and jujube polysaccharide. The cardiac muscle cell culture medium comprises an RPMI-1640 culture medium, trehalose, taurine, fibroblast growth factors, endothelial cell growth factors, potassium bicarbonate, amino acid chelated selenium, glutamine, progesterone, coenzyme I, lipoic acid, salvianolic acid B, polygonatum polysaccharide and ginsenoside.
Owner:广东科门生物科技有限公司

Method for separation and purification of human amniotic fluid stem cell

The invention discloses a method for separating and purifying human amniotic fluid stem cells. The method is to use an embryo antigen-4 at a special stage as a screening marker to separate and purify the human amniotic fluid stem cells which have homogeneous characteristics and are positively expressed by the embryo antigen-4 at the special stage from the human amniotic fluid stem cells which are adherently cultured. Experimental results show that the method can obtain the human amniotic fluid stem cells which have homogeneous characteristics, good capacities of proliferation and inductive differentiation, and cell ratio of G0 stage to G1 stage cells of more than 90 percent, and can express specificity markers of human totipotent stem cells such as the embryo antigen-4, Nanog and Oct-4 at the special stage. The invention provides a new way to obtain the human amniotic fluid stem cells, and lays a foundation for the further application of the human amniotic fluid stem cells.
Owner:FIELD OPERATION BLOOD TRANSFUSION INST OF PLA SCI ACAD OF MILITARY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products